Valeant Pharmaceuticals Under Fresh Scrutiny Over Drug Pricing

Valeant Pharmaceuticals disclosed late Wednesday that it was subpoenaed by U.S. prosecutors seeking information on its pricing programs. In early trading on Thursday, Valeant’s U.S.-listed shares were down 9% at $156.53. Valeant under fire for increasing drug prices Valeant Pharmaceuticals has received subpoenas from U.S. prosecutors seeking information on drug-pricing decisions. In a statement on Wednesday night, the Canada-based drug company said it recently received a subpoena from the U.S. Attorney’s Office in Massachusetts and another from the Manhattan U.S. Attorney’s Office seeking information on its patient assistance programs, drug distribution and pricing decisions. Laval, Quebec-based Valeant said the subpoenas mostly…